BFM
SCPH

Boothbay Fund Management’s scPharmaceuticals SCPH Stock Holding History

Boothbay Fund Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30,570
Closed -$312K – 2034
2023
Q2 		$312K Buy
30,570
+14,167
+86% +$148K 0.01% 1279
2023
Q1 		$149K Buy
16,403
+2,450
+18% +$18K ﹤0.01% 1825
2022
Q4 		$100K Sell
13,953
-26,798
-66% -$164K ﹤0.01% 1785
2022
Q3 		$266K Sell
40,751
-44,711
-52% -$239K 0.01% 1619
2022
Q2 		$412K Sell
85,462
-1,173
-1% -$5.8K 0.01% 1279
2022
Q1 		$492K Hold
86,635
– – 0.01% 1301
2021
Q4 		$435K Hold
86,635
– – 0.01% 1076
2021
Q3 		$576K Sell
86,635
-38,192
-31% -$228K 0.02% 1022
2021
Q2 		$763K Sell
124,827
-9,689
-7% -$58.4K 0.02% 812
2021
Q1 		$895K Sell
134,516
-16,183
-11% -$111K 0.03% 656
2020
Q4 		$797K Sell
150,699
-1,542
-1% -$12.1K 0.03% 579
2020
Q3 		$1.13M Buy
152,241
+30
+0% +$234 0.07% 393
2020
Q2 		$1.12M Buy
152,211
+36,823
+32% +$323K 0.08% 354
2020
Q1 		$854K Buy
+115,388
New +$837K 0.07% 338

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Boothbay Fund Management's SCPH Position: Q3 2023 in Review

Boothbay Fund Management sold out of scPharmaceuticals (SCPH) in Q3 2023, closing a stake of 30,570 shares — an estimated $312K sold.

Boothbay Fund Management first reported a position in SCPH in Q1 2020 and held it in 14 quarters. The position peaked at $1.13M in Q3 2020. 73 funds tracked by Wall St. Rank hold SCPH as of Q3 2023.

  • Boothbay Fund Management reported no remaining scPharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 30,570 scPharmaceuticals shares in Q3 2023, an estimated $312K.
  • Boothbay Fund Management first reported a position in scPharmaceuticals in Q1 2020 and held it in 14 quarters.
  • Boothbay Fund Management's scPharmaceuticals position peaked at $1.13M in Q3 2020.
  • 73 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2023.

Based on Boothbay Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.